Biomax Informatics Presents AILANI 2.0 for Even More Intelligent Responses
Biomax Informatics announces the launch of version 2.0 of AILANI. AILANI 2.0 represents an even more modern and user-friendly version of Biomax Informatics’ semantic search platform. Via the new AILANI Cloud Interface, users can quickly and cost-effectively search through numerous publicly accessible, academic full-text documents, news feeds, clinical studies, and COVID-19-relevant patents, receiving intelligent responses to their questions, alongside their keyword search. Unlike in the first version of AILANI, people using the AILANI Cloud benefit from a document tagging system for collaborative purposes, as well as from the introduction of “personas,” which enable a different experience for distinct user groups.
Through the new AILANI Enterprise solution, Biomax also offers customers the opportunity to integrate their own data – in both a structured and unstructured format – into the system, to expand the semantic search function to this data by means of AI algorithms, and to compare it with publicly accessible data. To increase acceptance among employees and to optimize integration into the system landscape, the portal can be quickly and easily adapted to the company’s corporate design. An optional group function (persona) enables the rapid exchange of data and responses within the team. This allows new ideas and new knowledge to be generated and shared more quickly. The time required for product development can be reduced considerably, decisions can be made more rapidly and in an enhanced manner, and competitive advantages can be realized.
“The experiences and feedback of our customers over the past year have shown us that we can make a valuable contribution to successful research and product development in the life sciences sector through AILANI,” says Dr. Sascha Losko, Director of Product Management. “With AILANI 2.0 and our new pricing model, we are also able to provide companies of any size with optimal access to our software.”
Through AILANI for COVID-19, Biomax Informatics began offering free access to AILANI back in spring 2020. Interested parties can try out AILANI for free at https://ailani.ai and get answers to specific questions relating to COVID-19.
Free Webinar about AILANI 2.0
Biomax will offer a free webinar on AILANI 2.0 at 3:00 p.m. on April 29, 2021. For more information, please visit our website at www.biomax.com/webinar or follow us on LinkedIn. Biomax experts are already looking forward to providing attendees with a detailed insight into AILANI 2.0.
About Biomax Informatics:
Biomax Informatics offers software solutions for better decision-making and optimal knowledge management in the life sciences industry. Using the company’s software, customers can generate added value through the integration of information from their own and public resources, enabling them to achieve a knowledge-based approach for the development of innovative life sciences products. Biomax’s global customers include clinics, companies, and research institutions successful in the fields of research into active substances, diagnostics, fine chemicals, and food and plant products. The company, which was founded in 1997 and currently has 45 members of staff, is headquartered in Planegg near Munich. Further information can be found at www.biomax.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005042/en/
Contact information
Your contact at Biomax:
Press contact:
Bettina von Klitzing-Stückle
Marketing Manager
Bettina.klitzing-stueckle@biomax.com
Customer contact:
Dr. Sascha Losko
Director of Product Management
Sascha.losko@biomax.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
Thales Powers CES*-Winning Post-Quantum Chip From Samsung Electronics7.1.2026 09:15:00 EET | Press release
Quantum computers, with their unprecedented processing power, will ultimately challenge today’s encryption standards. This is why Thales welcomes the CES 2026 recognition awarded to the new post-quantum–ready security chip from Samsung Electronics' System LSI Business, which embeds Thales’ secure operating system and quantum-resistant cryptographic libraries. This breakthrough represents a major step forward in protecting connected devices against both current cyberattacks and tomorrow’s quantum-era threats. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260106145232/en/ Thales’ hardened OS enables Samsung's award-winning security chip to deliver hardware-based, quantum-resistant protection from the moment devices power on. Ultimately, it ensures that encrypted data and device credentials remain secure against both classical and quantum attacks, preserving confidentiality, integrity and long-term trust, even in a post-quantu
Heath Hoglund Joins Sisvel as Chief IP Officer7.1.2026 08:00:00 EET | Press release
Sisvel is pleased to announce the appointment of Heath Hoglund as the company’s first-ever Chief Intellectual Property Officer. In this role he will be fully responsible for the firm’s patent pools on a global basis. One of the world’s top IP dealmakers, Hoglund joins Sisvel having taken the decision to leave Via Licensing, where he was an outstanding President for four years. Prior to that, he had been Vice-President of IP and Standards at Dolby, overseeing the company’s patent portfolio, its patent licensing programmes, and leading on the formation and design of numerous patent pools and standards initiatives. The appointment creates a new Licensing and Programme Management leadership structure at Sisvel. This will strengthen collaboration between the functions, increasing Sisvel’s considerable growth potential. Licensing and Programme Management heads, Nick Webb and David Muus, will continue to lead their respective areas, retaining all current responsibilities. Heath Hoglund’s trac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom